Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (131-140 of 432) with videos related to

Pageof 44
Sort By:
Leukemia Research|March 5, 2015
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failureStéphanie Harel, Amina Cherait, Céline Berthon, et al.
Blood|September 28, 2002
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)Claude Preudhomme, Christophe Sagot, Nicolas Boissel, et al.
International Journal of Cancer|December 6, 2008
Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: a French case-control studySara Villeneuve, Laurent Orsi, Alain Monnereau, et al.
The Lancet. Haematology|February 4, 2018
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trialHagop M Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Leukemia Research|August 20, 2013
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromesThomas Prebet, Thorsten Braun, Odile Beyne-Rauzy, et al.
Leukemia Research|February 19, 2013
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidineLionel Adès, Mikkael A Sekeres, Alice Wolfromm, et al.
Cancer|July 12, 2008
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.
Leukemia Research|May 11, 2010
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC studyNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.
Haematologica|March 16, 2012
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Pageof 44

Showing results (131-140 of 432) with videos related to

Sort By:
Pageof 44
Leukemia Research|March 5, 2015
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failureStéphanie Harel, Amina Cherait, Céline Berthon, et al.
Blood|September 28, 2002
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)Claude Preudhomme, Christophe Sagot, Nicolas Boissel, et al.
International Journal of Cancer|December 6, 2008
Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: a French case-control studySara Villeneuve, Laurent Orsi, Alain Monnereau, et al.
The Lancet. Haematology|February 4, 2018
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trialHagop M Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Leukemia Research|August 20, 2013
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromesThomas Prebet, Thorsten Braun, Odile Beyne-Rauzy, et al.
Leukemia Research|February 19, 2013
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidineLionel Adès, Mikkael A Sekeres, Alice Wolfromm, et al.
Cancer|July 12, 2008
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.
Leukemia Research|May 11, 2010
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC studyNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.
Haematologica|March 16, 2012
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesNorbert Gattermann, Carlo Finelli, Matteo Della Porta, et al.
Pageof 44